Last reviewed · How we verify
Placebo Part II
Placebo Part II is an inert substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo Part II |
|---|---|
| Also known as | iron sucrose injection - Venofer, regular dose of Daunorubicin (Arm I), higher dose of Daunorubicin (ArmI), Saline, Atacan Tab. 8 mg(or Atacan Tab. 16 mg), Norvasc Tab. 5 mg |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredient and produces therapeutic effects primarily through psychobiological mechanisms such as expectation and conditioning. It is used as a control or comparator in clinical trials and may be marketed for specific indications where placebo response is clinically relevant.
Approved indications
Common side effects
Key clinical trials
- Wireless Nerve Stimulation Device To Enhance Recovery After Stroke (NA)
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) (PHASE2, PHASE3)
- Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PHASE2)
- Assess Safety and Efficacy of VAD044 in HHT Patients (PHASE1, PHASE2)
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Part II CI brief — competitive landscape report
- Placebo Part II updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI